Poolbeg agrees 12-month option over potential Behcet's treatment
30th Apr 2024 16:43
(Sharecast News) - Poolbeg Pharma announced an exclusive 12-month option agreement with Silk Road Therapeutics on Tuesday, to potentially acquire a novel topical muco-adherent formulation of Pentoxifylline (tPTX).
Read morePoolbeg Pharma to be granted US patent
20th Mar 2024 11:10
(Sharecast News) - Biopharmaceutical company Poolbeg Pharma announced on Wednesday that it has received a notice of allowance from the US Patent Office regarding its immunomodulator II patent application.
Read moreDirector dealings: Poolbeg Pharma co-founder ups stake
19th Feb 2024 14:22
(Sharecast News) - Poolbeg Pharma revealed on Monday that chairman Cathal Friel had acquired 830,000 ordinary shares in the AIM-listed biopharmaceutical company.
Read morePoolbeg upbeat on research into potential drug market
12th Feb 2024 14:37
(Sharecast News) - Biopharmaceutical company Poolbeg Pharma announced findings from independent research confirming a substantial market opportunity exceeding $10bn for its drug candidate POLB 001 on Monday, in preventing cancer immunotherapy-induced cytokine release syndrome (CRS) through oral delivery.
Read morePoolbeg makes promising progress with RSV programme
20th Dec 2023 13:54
(Sharecast News) - Poolbeg Pharma revealed promising results from the lab-based analysis and prioritisation of respiratory syncytial virus (RSV) drug targets and treatments on Wednesday, driven by its artificial intelligence (AI) programme.
Read morePoolbeg gets notice of a new Japan patent
20th Sep 2023 12:16
(Sharecast News) - Clinical-stage biopharmaceutical company Poolbeg Pharma announced the receipt of a notice of allowance from the Japanese Patent Office for its Immunomodulator I patent application on Wednesday.
Read morePoolbeg reports progress with oral vaccine development
22nd Jun 2023 14:47
(Sharecast News) - Clinical-stage biopharmaceutical company Poolbeg Pharma updated the market on its oral vaccine programme on Thursday.
Read morePoolbeg expands its focus molecule into oncology
16th Jan 2023 15:48
(Sharecast News) - Poolbeg Pharma announced the strategic expansion of 'POLB 001' into oncology on Monday.
Read morePoolbeg identifies new drug candidates with OneThree
21st Dec 2022 13:37
(Sharecast News) - Biopharmaceutical company Poolbeg Pharma has successfully identified potential new drug candidates from its respiratory syncytial virus (RSV) artificial intelligence (AI) programme with OneThree Biotech, it announced on Wednesday.
Read morePoolbeg secures exclusive licence to possible obesity drug tech
14th Dec 2022 16:14
(Sharecast News) - Infectious disease-focussed biopharmaceutical company Poolbeg Pharma has acquired an exclusive licence from AnaBio sister company InsuCaps, it announced on Wednesday, to use its patented microencapsulation and nanoencapsulation oral delivery technologies in metabolic syndrome-related diseases, including obesity, pre-diabetes and diabetes.
Read morePoolbeg announces 'breakthrough' in AI drug target programme
8th Nov 2022 13:06
(Sharecast News) - Infectious disease pharmaceutical developer Poolbeg Pharma announced a "significant breakthrough" in its artificial intelligence (AI) programme with partner OneThree Biotech on Tuesday, through the discovery of novel drug targets for the treatment of respiratory syncytial virus (RSV).
Read morePoolbeg Pharma upbeat on US patent application progress
4th Oct 2022 14:14
(Sharecast News) - Infectious disease pharmaceutical company Poolbeg Pharma updated the market on its intellectual property (IP) position around 'POLB 001' on Tuesday, which it described as a small molecule immunomodulator for the treatment of severe influenza.
Read morePoolbeg inks exclusive deal for melioidosis vaccine candidate
21st Sep 2022 16:18
(Sharecast News) - Clinical-stage infectious disease pharmaceutical company Poolbeg Pharma has signed an exclusive licence agreement with University College Dublin (UCD), it announced on Wednesday, for a late preclinical-stage vaccine candidate for melioidosis.
Read morePoolbeg granted European patent for antiviral nose spray
14th Apr 2022 14:53
(Sharecast News) - Clinical-stage pharmaceutical company Poolbeg Pharma reported on the strengthening of its intellectual property (IP) for its 'POLB 002' asset on Thursday - a first-in-class, intranasally-administered RNA-based immunotherapy for respiratory virus infections.
Read morePoolbeg signs option deal for potential melioidosis vaccine
6th Dec 2021 15:23
(Sharecast News) - Clinical-stage infectious disease pharmaceutical company Poolbeg Pharma has signed an option agreement to licence 'MelioVac', a vaccine for melioidosis, with University College Dublin and its inventor Siobhán McClean, it announced on Monday, through the university's intellectual property office NovaUCD.
Read more